New data examines sustained glycemic control with exenatide once weekly vs. insulin glargine
Post-hoc analysis found that, despite continued titration with insulin glargine, more diabetes patients achieved sustained glycemic control with exenatide once-weekly, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
Post-hoc analysis found that, despite continued titration with insulin glargine, more diabetes patients achieved sustained glycemic control with exenatide once-weekly, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
Three-year data from the DURATION-3 trial, sponsored by AstraZeneca, were studied to explore the association between baseline characteristics or early (≤12 week) treatment responses with sustained glycaemic control, comparing exenatide once-weekly with titrated insulin glargine (glargine). Patients received exenatide once-weekly (n=233) or glargine (n=223) as add-on therapy to metformin alone or in combination with a sulphonylurea. Inability to achieve sustained glycaemic response was defined as HbA1c > 7% at 2 consecutive visits or HbA1c > 9% at 1 visit after 26 weeks of treatment.
In particular, the results showed the following:
· In the intent-to-treat patient population, 50% of the exenatide once weekly group achieved sustained glycemic control compared to 43% in the glargine group. Of those who completed 3 years, 43% and 33% respectively, achieved sustained glycemic control.
· Regardless of therapy, for every 1% elevation in baseline HbA1c (> 7%) the risk of losing glycaemic control increased by 90% (P=.0002).
· For every 10% higher baseline HOMA-B, the risk of losing glycaemic control decreased by 11% (P=.0288).
· The rate of weight change in weeks 1 through 8 was the most relevant early treatment response predictor of HbA1c control (P =.0640).
Baseline HbA1c and HOMA-B significantly impacted the odds of patients achieving sustained control.
Additionally, the results suggest the rate of weight change following treatment initiation [weeks 1 through 8] may potentially predict the probability of patients achieving longer-term sustained glycemic control in adult patients with type 2 diabetes, according to the study.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
